IP Library › Granted Patent US 11,591,390
Granted Patent B2
US 11,591,390 · App. 16/582,813 · Granted Feb 28, 2023

SIRP-α binding proteins and methods of use thereof

Inventors: Mahan Abbasian (San Diego, CA); Henry H. Chan (Poway, CA); Laure Escoubet (San Diego, CA); Gustavo Fenalti (San Diego, CA); Kandasamy Hariharan (San Diego, CA); Monica Wai Ling Leung (San Diego, CA); Konstantinos Mavrommatis (Concord, CA); David P. Mikolon (San Diego, CA); Heather K. Raymon (San Diego, CA); Carlo Steven Santos (San Diego, CA); Jeonghoon Sun (San Francisco, CA); Christina Valerie Trout (San Diego, CA)
Assignee: Celgene Corporation
C07K16/2803C07K16/2863C07K16/2896C07K2317/34C07K2317/565C07K2317/567C07K2317/732C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,591,390
App. No.
16/582,813
Granted
Feb 28, 2023
Kind
B2
Abstract

Provided herein are compositions, methods and uses involving antibodies that specifically bind to signal regulatory protein-α (SIRPα) and modulate the activity of SIRPα.

Claims (28)

1. An antibody or antigen-binding fragment thereof that binds to human SIRPα, wherein the antibody or the antigen-binding fragment thereof comprises:

(i) a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 having an amino acid sequence of a VL CDR1, a VL CDR2, and a VL CDR3, respectively, of a VL having the amino acid sequence of SEQ ID NO:67; and

(ii) a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 having an amino acid sequence of a VH CDR1, a VH CDR2, and a VH CDR3, respectively, of a VH having the amino acid sequence of SEQ ID NO:80.

2. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises:

(a) a VL comprising: a VL CDR1 comprising the amino acid sequence of SEQ ID NO:62, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:63, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:65; and

(b) a VH comprising: a VH CDR1 comprising the amino acid sequence of SEQ ID NO:78, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:69, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO:57.

3. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:67.

4. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:67.

5. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:80.

6. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:80.

7. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:67; and a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:80.

8. An antibody or antigen-binding fragment thereof that binds to human SIRPα, wherein the antibody or the antigen-binding fragment thereof comprises a VL comprising the amino acid sequence of SEQ ID NO:67; and a VH comprising the amino acid sequence of SEQ ID NO:80.

9. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:143.

10. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence of SEQ ID NO:143.

11. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:119.

12. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:119.

13. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a light chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:143, and a heavy chain comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:119.

14. An antibody that binds to human SIRPα, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:143, and a heavy chain comprising the amino acid sequence of SEQ ID NO:119.

15. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antigen-binding fragment is a Fab, Fab′, (Fab′) 2 , Fv, or scFv fragment.

16. The antibody or the antigen-binding fragment of claim 8 , wherein the antigen-binding fragment is a Fab, Fab′, (Fab′) 2 , Fv, or scFv fragment.

17. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a human IgG1 Fc region or a mutant thereof.

18. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain Fc region comprising the amino acid sequence selected from the group consisting of SEQ ID NOS:144 and 155-159.

19. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof further comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO:211.

20. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof comprises: a light chain constant region comprising the amino acid sequence of SEQ ID NO:211; and a heavy chain Fc region comprising the amino acid sequence selected from the group consisting of SEQ ID NOS:144 and 155-159.

21. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody is a monoclonal antibody.

22. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody is a humanized, human, or chimeric antibody.

23. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment thereof is conjugated to an agent.

24. The antibody or the antigen-binding fragment thereof of claim 23 , wherein the agent is selected from the group consisting of a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound, and a chemiluminescent compound.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2020
From: ABBASIAN, MAHAN; CHAN, HENRY H.; ESCOUBET, LAURE; FENALTI, GUSTAVO; HARIHARAN, KANDASAMY; LEUNG, MONICA WAI LING; MIKOLON, DAVID P.; RAYMON, HEATHER K.; SANTOS, CARLO STEVEN; SUN, JEONGHOON; TROUT, CHRISTINA VALERIE
To: SIGNAL PHARMACEUTICALS, LLC
Reel/Frame 051604/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2020
From: MAVROMMATIS, KONSTANTINOS
To: CELGENE CORPORATION
Reel/Frame 051604/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2020
From: SIGNAL PHARMACEUTICALS, LLC
To: CELGENE CORPORATION
Reel/Frame 051604/0359 →
Continuity (4)
Continuation PCTUS2019052604 · Sep 24, 2019
Provisional Application 62853997 · May 29, 2019
Provisional Application 62737782 · Sep 27, 2018
Related Publication 20200102387A1 · Apr 2, 2020